Efficacy of the use of unsaponifiable fractions of avocado and soybean oil in osteoarthritis Review article
Article Sidebar
Published:
Jun 30, 2021
Keywords:
osteoarthritis of the knee joints, pharmacological treatment, unsaponifiable fractions of avocado and soybean oil
Main Article Content
Abstract
Osteoarthritis, which affects approximately 18% of women and 10% of men after the age of 60, is undoubtedly a serious public problem. The main pathological changes in osteoarthritis include the degeneration and loss of articular cartilage, changes in the subchondral bone and osteophyte formation in the bone epiphyses. Pain accompanying degenerative modifications significantly reduces the quality of life of patients. The purpose of this article is to discuss the use of unsaponifiable fractions of avocado and soybean oil to control the symptoms of osteoarthritis of the knee on a case-by-case basis.
Article Details
How to Cite
Walewska, E. (2021). Efficacy of the use of unsaponifiable fractions of avocado and soybean oil in osteoarthritis. Medycyna Faktow (J EBM), 14(2(51), 188-192. https://doi.org/10.24292/01.MF.0221.8
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Zhang W, Doherty M, Peat G et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010; 69(3): 483-9.
2. Nelson AE. Osteoarthritis year in review 2017: clinical. Osteoarthritis Cartilage. 2018; 26(3): 319-25.
3. Jordan KM, Arden NK, Doherty M et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62(12): 1145-55.
4. Salehi B, Rescigno A, Dettori T et al. Avocado-soybean unsaponifiables: a panoply of potentialities to be exploited. Biomolecules. 2020; 10(1): 130.
5. Henrotin YE, Sanchez CH, Deberg MA et al. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. J Rheumatol. 2003; 30(8): 1825-34.
6. Altinel L, Saritas ZK, Kose KC et al. Treatment with unsaponifiable extracts of avocado and soybean increases TGF-β1 and TGF-β2 levels in canine joint fluid. Tohoku J Exp Med. 2007; 211(2): 181-6.
7. Gabay O, Gosset M, Levy A et al. Stress-induced signaling pathways in hyalin chondrocytes: inhibition by Avocado-Soybean Unsaponifiables (ASU). Osteoarthritis Cartilage. 2008; 16(3): 373-84.
8. Ownby SL, Fortuno LV, Au AY et al. Expression of pro-inflammatory mediators is inhibited by an avocado/soybean unsaponifiables and epigallocatechin gallate combination. J Inflamm. 2014; 11(1): 1-7.
9. Kut‐Lasserre C, Miller CCh, Ejeil AL et al. Effect of avocado and soybean unsaponifiables on gelatinase A (MMP‐2), stromelysin 1 (MMP‐3), and tissue inhibitors of matrix metalloproteinase (TIMP‐1 and TIMP‐2) secretion by human fibroblasts in culture. J Periodontol. 2001; 72(12): 1685-94.
10. Angermann P. Avocado/soybean unsaponifiables in the treatment of knee and hip osteoarthritis. Ugeskr Laeger. 2005; 167(33): 3023-5.
11. Blotman F, Maheu E, Wulwik A et al. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum Engl Ed. 1997; 64(12): 825-34.
12. Appelboom T, Schuermans J, Verbruggen G et al. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. Scand J Rheumatol. 2001; 30(4): 242-7.
13. Maheu E, Cadet Ch, Marty M et al. Randomised, controlled trial of avocado–soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis. 2014. 73(2): 376-84.
14. Darestani RT, Bakhshi H, Sahraee R. Comparing the efficacy and safety of Diclofenac and Piascledine in patients with knee osteoarthritis. Pajoohandeh Journal. 2013; 17(6): 272-8.
15. Pavelka K, Coste P, Géher P et al. Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clin Rheumatol. 2010; 29(6): 659-70.
16. Głuszko P, Stasiek M. Symptom-modifying effects of oral avocado/soybean unsaponifiables in routine treatment of knee osteoarthritis in Poland. An open, prospective observational study of patients adherent to a 6-month treatment. Reumatologia. 2016; 54(5): 217.
2. Nelson AE. Osteoarthritis year in review 2017: clinical. Osteoarthritis Cartilage. 2018; 26(3): 319-25.
3. Jordan KM, Arden NK, Doherty M et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62(12): 1145-55.
4. Salehi B, Rescigno A, Dettori T et al. Avocado-soybean unsaponifiables: a panoply of potentialities to be exploited. Biomolecules. 2020; 10(1): 130.
5. Henrotin YE, Sanchez CH, Deberg MA et al. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. J Rheumatol. 2003; 30(8): 1825-34.
6. Altinel L, Saritas ZK, Kose KC et al. Treatment with unsaponifiable extracts of avocado and soybean increases TGF-β1 and TGF-β2 levels in canine joint fluid. Tohoku J Exp Med. 2007; 211(2): 181-6.
7. Gabay O, Gosset M, Levy A et al. Stress-induced signaling pathways in hyalin chondrocytes: inhibition by Avocado-Soybean Unsaponifiables (ASU). Osteoarthritis Cartilage. 2008; 16(3): 373-84.
8. Ownby SL, Fortuno LV, Au AY et al. Expression of pro-inflammatory mediators is inhibited by an avocado/soybean unsaponifiables and epigallocatechin gallate combination. J Inflamm. 2014; 11(1): 1-7.
9. Kut‐Lasserre C, Miller CCh, Ejeil AL et al. Effect of avocado and soybean unsaponifiables on gelatinase A (MMP‐2), stromelysin 1 (MMP‐3), and tissue inhibitors of matrix metalloproteinase (TIMP‐1 and TIMP‐2) secretion by human fibroblasts in culture. J Periodontol. 2001; 72(12): 1685-94.
10. Angermann P. Avocado/soybean unsaponifiables in the treatment of knee and hip osteoarthritis. Ugeskr Laeger. 2005; 167(33): 3023-5.
11. Blotman F, Maheu E, Wulwik A et al. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum Engl Ed. 1997; 64(12): 825-34.
12. Appelboom T, Schuermans J, Verbruggen G et al. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. Scand J Rheumatol. 2001; 30(4): 242-7.
13. Maheu E, Cadet Ch, Marty M et al. Randomised, controlled trial of avocado–soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis. 2014. 73(2): 376-84.
14. Darestani RT, Bakhshi H, Sahraee R. Comparing the efficacy and safety of Diclofenac and Piascledine in patients with knee osteoarthritis. Pajoohandeh Journal. 2013; 17(6): 272-8.
15. Pavelka K, Coste P, Géher P et al. Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clin Rheumatol. 2010; 29(6): 659-70.
16. Głuszko P, Stasiek M. Symptom-modifying effects of oral avocado/soybean unsaponifiables in routine treatment of knee osteoarthritis in Poland. An open, prospective observational study of patients adherent to a 6-month treatment. Reumatologia. 2016; 54(5): 217.